Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD)
Background The European Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (EUROSTAD) is an ongoing observational study aiming to describe characteristics of patients with atopic dermatitis (AD) treated with systemic therapy over time and the management o...
Saved in:
Main Authors: | Marjolein de Bruin-Weller, Andrew E. Pink, Silvia M. Ferrucci, Annalisa Patrizi, Ake Svensson, Marie L. A. Schuttelaar, Marie Tauber, Marius Ardeleanu, Shyamalie Jayawardena, Moataz Daoud |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-07-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2022.2038361 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluating the Real-World Effectiveness of Systemic Treatments in Atopic Dermatitis Using the Atopic Dermatitis Control Tool (ADCT): A Multi-Centre, Prospective Study
by: Hyun Ji Lee, et al.
Published: (2025-02-01) -
Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis
by: C. Grote, et al.
Published: (2025-12-01) -
Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review
by: Lauletta G, et al.
Published: (2025-01-01) -
Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study
by: Filip Rob, et al.
Published: (2025-12-01) -
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
by: Tiago Torres, et al.
Published: (2024-04-01)